| Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL 2025 · omega-3 FA supplementation arm · US men aged 50 years or older and women aged 55 years or older in a primary-prevention trial | 1 g | 840 mg | 5 years | 12,933 |
| The impact of pre- and postnatal exposures on allergy related diseases in childhood: a controlled multicentre intervention study in primary health care 2013 · intervention cohort · Pregnant women and their children in the general population of Trondheim; no age range or sex restriction stated | 5 mL | 1.2 g | — | 1,374 |
| Fish oil intake compared with olive oil intake in late pregnancy and asthma in the offspring: 16 y of registry-based follow-up from a randomized controlled trial 2008 · fish oil · Women with normal pregnancies, recruited around gestation week 30 | 4 g | 2.7 g | — | 266 |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 1 g | 840 mg | 1936 days | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 1 g | 840 mg | 1936 days | — |
| Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial 2023 · Multidomain plus omega 3 · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed | 400 mg | 400 mg | 3 years | 129 |
| Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial 2023 · Omega 3 alone · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed | 400 mg | 400 mg | 3 years | 112 |
| Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development 2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required | 2 mL | 300 mg | 26 weeks | 87 |
| Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA) 2023 · MAG-EPA intervention group · Adult men with aggressive localized prostate cancer (Gleason score ≥ 7, ISUP Grade group ≥ 2) treated by radical prostatectomy | 3.75 g | 3.3 g | 1 year | 65 |
| Untitled 2012 · omega-3 PUFA · Healthy adults aged 51–72 years, women and men, with BMI 20–30 kg/m² and no known metabolic disease or cognitive decline | 5 g | 3 g | 5 weeks | 38 |
| A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine 2024 · EPA group · Adults with episodic migraine; age and sex range not reported | 2 g | 1.8 g | 12 weeks | 35 |
| Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome 2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation | 10 mL | 242 mg/kg | 1 year | 33 |
| Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial 2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day | 5 g | 900 mg | 90 days | 27 |
| Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial 2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder | 1.35 g | 2.13 g | 12 weeks | 27 |
| Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus 2015 · fish oil · Adults aged 18–64 with systemic lupus erythematosus | 2.25 g | 4.5 g | 26 weeks | 25 |
| Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial 2020 · TG1 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis | 3 g | 900 mg | 60 days | 25 |
| Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial 2020 · TG2 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis | 3 g | 900 mg | 60 days | 25 |
| The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial 2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery | 2 g | 940 mg | 30 days | 18 |
| [Polyunsaturated omega-3 fatty acids in the treatment of experimental human gingivitis] 1996 · treatment group · Healthy volunteers; age and sex not specified; no stated condition | 6 g | 1.8 g | 7 days | 18 |
| Pilot study on n-3 polyunsaturated fatty acids in the treatment of human experimental gingivitis 1997 · drug (fish oil) group · Healthy volunteers with experimentally induced gingivitis; age and sex not stated | 6 g | 1.8 g | 8 days | 18 |
| Fish oil supplemented for 9 months does not improve glycaemic control or insulin sensitivity in subjects with impaired glucose regulation: a parallel randomised controlled trial 2016 · Fish oil (FO) · Adults with impaired glucose regulation; age and sex not reported | 6 g | 3.9 g | 270 days | 16 |
| Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment 2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified | 2.4 g | 1.6 g | 24 weeks | 15 |
| Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial 2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis | 1 g | 300 mg | 90 days | 15 |
| Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females 2015 · fish oil (FO) · Community-dwelling females aged 60–76 years in generally good health, with low fish intake and no omega-3 supplement use | 5 g | 3 g | 12 weeks | 12 |
| Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial 2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition | 2.4 g | 600 mg | 62 days | 12 |
| Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults 2020 · Fish oil group · Healthy physically active men and women aged 60–75 years | 5 g | 2 g | 12 weeks | 12 |
| Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions 2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition | 2.4 g | 600 mg | 62 days | 10 |
| The effect of fish oil supplementation on resistance training-induced adaptations 2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease | 4.5 g | 2.28 g | 10 weeks | 10 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Omega-3 + USRPT (OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 1 g | 680 mg | 8 weeks | 10 |
| Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors 2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training | 2.4 g | 600 mg | 62 days | 8 |
| Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes 2003 · n-3 PUFA diet · Elite athletes, including athletes with exercise-induced bronchoconstriction (EIB) and athletes without EIB; age and sex not reported | 3.2 g | — | 3 weeks | 5 |
| Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids 2001 · dietary n-3FA therapy · Patients with sickle cell disease; age and sex not stated | 250 mg/kg | 100 mg/kg | 30 days | — |
| Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial 1992 · fish oil · Patients with ulcerative colitis, including patients entering in relapse and patients in remission | 20 mL | 4.5 g | 1 year | — |
| Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers 2007 · fish oil supplementation · Healthy men aged 26.0 ± 3.1 years | 7.2 g | 1.8 g | 4 weeks | — |
| Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study 2007 · fish oil group · Women with type 2 diabetes without hypertriglyceridemia | 3 g | 1.8 g | 60 days | — |
| The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study 2011 · drug group · Adults aged 65 years or older with mild to moderate depression | 1 g | 300 mg | 26 weeks | — |
| Fish oil supplementation improves neutrophil function during cancer chemotherapy 2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated | 2 g | 300 mg | 8 weeks | — |
| Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study 1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported | 1.71 g | 1.71 g | 1 year | — |
| Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis 1993 · fish-oil group · Patients with moderate-to-severe psoriasis; age and sex not specified | 6 g | 5 g | 120 days | — |
| The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial 2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition | 2 g | 1 g | 18 weeks | 134 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 2 g | 1.42 g | 12 weeks | 40 |
| Lipid Profile, Lipoprotein Subfractions, and Fluidity of Membranes in Children and Adolescents with Depressive Disorder: Effect of Omega-3 Fatty Acids in a Double-Blind Randomized Controlled Study 2020 · Om3 group · Children and adolescents aged 11–17 years with depressive disorder or mixed anxiety and depressive disorder | 20 mL | 4.15 g | 12 weeks | 29 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 2 g | 600 mg | 120 days | 26 |
| Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial 2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis | 20 mL | 2.6 g | 26 weeks | 24 |
| Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial 2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis | 20 mL | 2.6 g | 90 days | 20 |
| An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553] 2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress | 2 g | 120 mg | 6 weeks | 16 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Probiotics + Omega-3 + USRPT (PRO + OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 1 g | 680 mg | 8 weeks | 10 |
| Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients 1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported | 216 mg | 216 mg | 6 weeks | — |
| Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial 2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms | 706 mg | 706 mg | 90 days | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 3 g | 1.95 g | 16 weeks | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 3 g | 1.95 g | 16 weeks | — |
| Evaluating the Impact of Omega-3 Fatty Acid (Soloways(TM)) Supplementation on Lipid Profiles in Adults with PPARG Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial 2023 · omega-3 fatty acids group · Adults aged 40–75 with LDL-C levels of 70–190 mg/dL and low-to-moderate cardiovascular risk, including participants with and without PPARG polymorphisms | 2 g | 1.8 g | 90 days | 51 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · FO concentrate · Obese men and women with BMI >30 | 4 g | 1.6 g | 12 weeks | 12 |
| Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis 2016 · Fish oil providing 0.7 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31. | 700 mg | 700 mg | 8 weeks | — |
| Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis 2016 · Fish oil providing 1.8 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31. | 1.8 g | 1.8 g | 8 weeks | — |
| Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial 2018 · ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported | 6 g | 3.65 g | 12 weeks | — |
| Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial 2018 · LCHP+ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported | 6 g | 3.65 g | 12 weeks | — |
| Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the Trials of Hypertension Prevention 1994 · fish oil group · Normotensive men and women aged 30–54 years | 6 g | 3 g | 26 weeks | — |
| Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol 2017 · Omega3Q10 treatment group · Adults aged at least 50 years with elevated blood pressure and/or elevated blood cholesterol | 1 g | 514 mg | 12 weeks | 48 |
| Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects 2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia | 9.6 g | 1.7 g | 4 weeks | 21 |
| Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration: A randomized, double-blind, crossover study 2023 · phospholipid-enhanced fish oil (PEFO) · Healthy adult men and women | 1 g | — | 1 day | 24 |
| Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease 1995 · fish-oil group · Patients with coronary artery disease; age range and sex not stated | 4 g | 3.4 g | 39 weeks | 260 |
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 3.36 g | 1.86 g | 1 year | 147 |
| Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease 2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported | 1 g | 650 mg | 1 year | 50 |
| Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication | 4.4 g | 4.4 g | 30 days | 40 |
| A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial 2019 · Omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation | 2 g | 1.4 g | 12 weeks | 35 |
| Effect of chia seeds or concentrated fish oil on cardiometabolic risk markers in subjects with hypertriglyceridaemia: a parallel clinical trial 2024 · low-calorie diet with concentrated fish oil · Patients with hypertriglyceridaemia; age and sex not specified | 1.8 g | 1.8 g | 8 weeks | 22 |
| Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome 2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m² | 2.15 g | 2.15 g | 6 weeks | 21 |
| Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men 2014 · LC n-3 PUFA supplementation · Men aged 24–48 years: 10 normolipidemic and 10 with mild combined hyperlipidemia | 5.04 g | 2.52 g | 12 weeks | 20 |
| Effects of Long Chain Omega-3 Polyunsaturated Fatty Acids on Brain Function in Mildly Hypertensive Older Adults 2018 · LCn-3PUFA group · Adults aged 40–85 with borderline or mild hypertension and low fish/seafood intake | 1.6 g | 2 g | 20 weeks | 19 |
| Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial 2012 · oxidised fish oil · Healthy adults aged 18–50 years | 8 g | 1.6 g | 7 weeks | 18 |
| Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial 2012 · fish oil · Healthy adults aged 18–50 years | 8 g | 1.6 g | 7 weeks | 17 |
| Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach 2014 · FO group · Healthy men and women aged 18–50 years | 8 g | 700 mg | 7 weeks | 17 |
| Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial 2019 · FO (fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women | 2 g | 1.2 g | 12 weeks | 17 |
| Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial 2019 · CC-FO (curcumin plus fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women | 2 g | 1.2 g | 12 weeks | 16 |
| Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial 2025 · EPA-rich fish oil · Adults aged 18–65 with non-severe burns covering less than 20% of total body surface area | 1.5 g | 2.1 g | 3 weeks | 12 |
| Effect of 21-Day Omega-3 Polyunsaturated Fatty Acid Supplementation on Exercise-Induced Secretory Factors and Inflammation Status in Young Men: A Randomized Double-Blind Trial 2026 · supplementation group · Physically active, healthy men aged approximately 22 years | 5 g | 3.25 g | 3 weeks | 12 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 4.4 g | 4.4 g | 90 days | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 4.4 g | 4.4 g | 90 days | 11 |
| n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes 2016 · n-3 PUFA (fish oil) supplementation · Men with type 2 diabetes; mean age 54.7 ± 7.6 years | 5 g | 3 g | 8 weeks | 10 |
| Effect of dietary n-3 PUFA supplementation on the muscle transcriptome in older adults 2016 · n-3 PUFA group · Healthy men and women aged 60–85 years | 4 g | 3.36 g | 26 weeks | 10 |
| Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study 1996 · Fish oil (FO) · Patients with hyperlipidemic non-insulin-dependent diabetes mellitus; age and sex not reported | 22 mL | 4.6 g | 2 weeks | 10 |
| Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study 1994 · fish oil group · Adults with non-insulin-dependent diabetes mellitus (NIDDM) | 5 g | 2.5 g | 6 weeks | 9 |
| Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics 1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract | 4 g | 1.4 g | 12 days | — |
| Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion 1999 · fish oil supplement group · Human volunteers; age, sex, and health status not specified | 20 mL | 3.6 g | 15 days | — |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 9 g | 2.1 g | 12 weeks | — |
| Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study 2004 · n-3 PUFA group · Healthy adult males | 12 g | 4 g | 8 weeks | — |
| Treatment for 6 months with fish oil-derived n-3 polyunsaturated fatty acids has neutral effects on glycemic control but improves dyslipidemia in type 2 diabetic patients with abdominal obesity: a randomized, double-blind, placebo-controlled trial 2017 · fish oil group · Adults with type 2 diabetes and abdominal obesity; mean age 65.4 years; 35 men and 64 women completed the study | 4 g | 2.4 g | 26 weeks | — |
| Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects 2020 · Saury oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease | 12 g | 3.4 g | 8 weeks | — |
| Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects 2020 · Control oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease | 12 g | 3 g | 8 weeks | — |
| Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial 2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications | 3 g | 1.1 g | 12 weeks | — |
| A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial 2019 · PS plus omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation | 2 g | 1.4 g | 12 weeks | 41 |
| The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial 2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program | 6 g | 3.6 g | 4 weeks | 11 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 1.05 g | 1.05 g | — | 10 |
| Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects 2009 · fish oil capsules · Hypertriglyceridaemic volunteers recruited from the Wollongong community; age and sex not reported | 1 g | 1.05 g | 6 weeks | — |
| Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial 2022 · Active treatment group · Adults aged 65–80 with low-grade inflammation (hs-CRP 1.5–6 mg/L) and BMI 18.5–27 kg/m² | 1.1 g | 640 mg | 8 weeks | — |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 180 mg | 180 mg | 4 weeks | — |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 225 mg | 3 years | 401 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 225 mg | 3 years | 399 |